Status:
UNKNOWN
Find the Adequate Dose of Nalbuphine for Laparoscopic Cholecystectomy
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Conditions:
Post Operative Pain
Opioid Side Effects
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
This study evaluate the adequate dose of mutonpain for laparoscopic cholecystectomy in the management of post operative pain. The investigators will randomize patients into three groups to compare the...
Detailed Description
Nalbuphine is a FDA approved noncontrolled drug of opioid. And it had been applied for post operative pain for different surgeries, claiming that less nausea and vomiting with the same analgesic effec...
Eligibility Criteria
Inclusion
- patient accept laparoscopic cholecystectomy
- age:20-80 years old
Exclusion
- nalbuphine allergy
- chronic pain
- active liver disease that would affect metabolization of nalbuphine
- patient who had regular pain medications
- patient who could not cooperate to the evaluation of the survey
- dementia or other psychiatric disease
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04135534
Start Date
November 1 2019
End Date
December 1 2020
Last Update
October 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan, 807